These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 34983660)
1. Future of anti-VEGF: biosimilars and biobetters. Kapur M; Nirula S; Naik MP Int J Retina Vitreous; 2022 Jan; 8(1):2. PubMed ID: 34983660 [TBL] [Abstract][Full Text] [Related]
2. Biosimilars in ophthalmology: "Is there a big change on the horizon?". Sharma A; Reddy P; Kuppermann BD; Bandello F; Lowenstein A Clin Ophthalmol; 2018; 12():2137-2143. PubMed ID: 30498330 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192 [TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516 [TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915 [TBL] [Abstract][Full Text] [Related]
6. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709 [TBL] [Abstract][Full Text] [Related]
7. Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general overview. Viola P; Testa V; Ferro Desideri L; Di Cello L; Rutigliani C; Vagge A; Nicolò M; Cian R; Traverso CE Drugs Today (Barc); 2021 Nov; 57(11):689-697. PubMed ID: 34821882 [TBL] [Abstract][Full Text] [Related]
8. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs. Zhang C; Friedman S; Mruthyunjaya P; Parikh R Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR; JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850 [TBL] [Abstract][Full Text] [Related]
11. Aflibercept: an update on recent milestones achieved. Palejwala NV; Lauer AK Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083 [TBL] [Abstract][Full Text] [Related]
12. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study. Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339 [TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. Pennington B; Alshreef A; Flight L; Metry A; Poku E; Hykin P; Sivaprasad S; Prevost AT; Vasconcelos JC; Murphy C; Kelly J; Yang Y; Lotery A; Williams M; Brazier J Pharmacoeconomics; 2021 Aug; 39(8):913-927. PubMed ID: 33900585 [TBL] [Abstract][Full Text] [Related]
14. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110 [TBL] [Abstract][Full Text] [Related]
15. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. Shah CP; Heier JS Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479 [TBL] [Abstract][Full Text] [Related]